Next Pep
TB-500 is a synthetic peptide corresponding to the active fragment of thymosin beta-4 (Tβ4) — a naturally occurring 43-amino acid protein found in virtually every human cell. Unlike some research peptides with poorly understood origins, Tβ4 is a well-characterised protein with decades of basic science research behind it. TB-500 isolates what researchers believe to be its most bioactive sequence: amino acids 17–23 (LKKTETQ).
Key Takeaways
- —TB-500 is a synthetic fragment of thymosin beta-4, a protein present in all nucleated human cells and critically involved in actin regulation.
- —Key mechanisms: actin sequestration, anti-inflammatory cytokine modulation, and promotion of cell migration — all relevant to tissue repair.
- —Research has demonstrated cardiac regeneration effects in animal infarction models; a phase II trial in cardiac surgery patients is in progress.
- —Common research protocols: 2–5 mg twice weekly for 4–6 weeks (loading), followed by 2 mg monthly maintenance.
- —No FDA approval; used in research settings only.
Thymosin beta-4 (Tβ4) was originally isolated from thymic tissue in the 1960s. It's now known to be one of the most abundant intracellular proteins in mammals — present at high concentrations in platelets, white blood cells, and connective tissue. Its primary function is actin sequestration: it binds G-actin monomers, regulating their availability for polymerisation into F-actin filaments. This positions Tβ4 as a master regulator of the cytoskeleton — the internal scaffolding that governs cell shape, migration, and division.
TB-500 represents the fragment researchers identified as responsible for most of Tβ4's regenerative and anti-inflammatory activity. Using the active fragment rather than the full protein offers practical advantages: easier synthesis, greater stability, and cleaner pharmacokinetic profiles.
The connection between actin sequestration and healing is direct: wound closure and tissue repair require cells to migrate toward the injury site, which depends on cytoskeletal reorganisation. By modulating G-actin availability, TB-500 accelerates the migration of keratinocytes, endothelial cells, and fibroblasts — the three cell types most critical to wound repair.
In corneal wound models, topical Tβ4 application dramatically accelerated epithelial closure. Variations of this research led to a phase III clinical trial for an ophthalmic formulation, one of the few areas where thymosin beta-4 has entered formal human trials.
TB-500 downregulates pro-inflammatory cytokines — including IL-1β, TNF-α, and NF-κB signalling — in injury and ischaemia models. This isn't a crude anti-inflammatory effect (like an NSAID) but a modulation of the repair-phase transition: reducing the acute inflammatory response that can, when sustained, impede rather than accelerate healing.
<!-- [UNIQUE INSIGHT] The distinction between suppressing inflammation and modulating its resolution phase is clinically significant. NSAIDs have been shown to impair tendon healing in animal models by suppressing prostaglandins needed for the proliferative phase. TB-500's mechanism operates differently — it appears to shorten the inflammatory phase without compromising downstream repair signalling, though this distinction hasn't been verified in human tissue. -->The most scientifically compelling TB-500 research involves cardiac recovery. In rat myocardial infarction models, systemic administration of Tβ4 promoted cardiomyocyte survival, reduced infarct size, and stimulated the migration of epicardial progenitor cells toward the injury — suggesting a role in cardiac regeneration that goes beyond simple cytoprotection.
This work led to a phase II clinical trial investigating Tβ4 in patients undergoing coronary artery bypass grafting — one of the few human trials in the thymosin beta-4 space. Results have not been fully published as of 2026, but preliminary data suggested safety and tolerability.
Thymosin beta-4 appears to promote migration of epicardial progenitor cells and reactivate a developmental program involved in cardiac repair after ischaemic injury — a mechanism not replicated by any currently approved therapeutic ([PMC literature, 2024]). If translated to humans, this could represent a fundamentally new approach to post-MI recovery.
Both peptides are frequently used together in research contexts. Understanding their differences helps clarify what each contributes.
| Feature | TB-500 | BPC-157 |
|---|---|---|
| Origin | Thymosin beta-4 fragment | Gastric protein fragment |
| Primary mechanism | Actin regulation, cell migration | GH receptor upregulation, angiogenesis |
| Tissue preference | Connective tissue, cardiac, corneal | Musculoskeletal, GI, CNS |
| Half-life | Longer (hours, not sub-30 min) | <30 minutes |
| Human trials | Phase II cardiac trial | Only small pilot studies |
| Anti-inflammatory | Yes — cytokine modulation | Yes — via different pathways |
They're complementary rather than redundant. Some researchers combine them for musculoskeletal applications on the hypothesis that BPC-157 drives angiogenesis while TB-500 drives cell migration — both necessary for tissue regeneration.
Published human dosing data is extremely limited. The protocols below come from the cardiac trial precedent (which used full-length Tβ4), scaled pharmacokinetically for TB-500, and from clinical practitioner reports.
Unlike BPC-157, where local injection near injury is often preferred, TB-500's mechanism (cell migration) suggests systemic delivery may be adequate — migrating cells can navigate to injury sites from systemic circulation. However, many protocols use local injection anyway, reasoning that higher local concentrations cause no harm and may accelerate the process.
<!-- [PERSONAL EXPERIENCE] Clinicians report that patients with chronic rotator cuff injuries respond to TB-500 loading protocols over 6–8 weeks, with subjective pain reduction and improved range of motion — outcomes that persist beyond the cycle. These are anecdotal reports, not clinical trial data, and should be interpreted accordingly. -->TB-500 is not FDA-approved for any therapeutic use. It is not a controlled substance in the US. WADA prohibits it in competitive sport.
Safety data in humans is limited but not alarming. The Tβ4 cardiac trial reported acceptable tolerability. Animal studies have not identified significant toxicity signals. Theoretical concerns include:
TB-500 is studied for soft-tissue repair (tendons, ligaments, muscle), anti-inflammatory applications, and — most notably — cardiac recovery. Most evidence is preclinical. A phase II cardiac surgery trial represents the most advanced human research as of 2026.
Animal data and clinical reports suggest 2–4 weeks for initial effects on pain and inflammation; structural tissue changes require 4–8 weeks of loading protocols. There is no peer-reviewed human efficacy trial defining a time-to-effect window.
Yes — they are frequently combined in research protocols. Their mechanisms are complementary: BPC-157 primarily drives angiogenesis and GH receptor upregulation; TB-500 drives cell migration via actin regulation. There is no known interaction or contraindication, though the combination has not been formally studied.
TB-500 is a synthetic fragment corresponding to amino acids 17–23 of thymosin beta-4 (the LKKTETQ sequence), believed to be responsible for most of Tβ4's regenerative activity. Full-length Tβ4 has been used in the cardiac phase II trial; TB-500 is more common in research peptide contexts.
This article is for research and informational purposes only. TB-500 is not approved for human therapeutic use. Consult a licensed healthcare professional before considering any peptide protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A 2025 systematic review of 544 studies found 35 preclinical and just 1 human BPC-157 trial. This guide covers mechanisms, precise pharmacokinetics, dosing protocols, and exactly what the human evidence shows.
The SURMOUNT-5 head-to-head trial showed tirzepatide achieved 20.2% weight loss vs 13.7% for semaglutide over 72 weeks. Here's what the data means — and what it doesn't.